

One is the new six: The International Society of Urological Pathology (ISUP) patient-focused approach to Gleason grading

John R. Srigley, MD;¹ Brett Delahunt, MD;² Lars Egevad, MD;³ Hemamali Samaratunga, MD;⁴ John Yaxley, MD;⁵ Andrew J. Evans, MD⁶

¹Trillium Health Partners and University of Toronto, Mississauga, ON, Canada; ²Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand; ³Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden; ⁴Aquesta UroPathology and University of Queensland, Brisbane, Queensland, Australia; ⁵Department of Urology, Royal Brisbane Hospital and University of Queensland, Brisbane, Queensland, Australia; ⁶University Health Network and University of Toronto, Toronto, ON, Canada

Cite as: *Can Urol Assoc J* 2016;10(9-10):339-41. <http://dx.doi.org/10.5489/cuaj.4146>

Fifty years ago, Donald Gleason published his eponymous grading system and demonstrated its prognostic utility in clinical trials designed to investigate hormonal therapies for prostate cancer.¹ Over the ensuing decades, the Gleason system has been widely used in clinical practice and research, and has been endorsed as the global grading standard for prostate cancer by numerous organizations, including the World Health Organization (WHO) and the Union for International Cancer Control (UICC).^{2,3}

The diagnosis and treatment of prostate cancer has changed dramatically in recent decades and as the new millennium dawned, a modernization of the Gleason system commenced. In 2005, the International Society of Urological Pathology (ISUP) convened a consensus conference at which the patterns comprising the various Gleason grades were clarified, along with the practical rules for their application.⁴ There was emphasis on how the grading system should be employed in biopsy practice. It was agreed that Gleason grades 1 and 2 should not be used in biopsy reporting. The consensus was that these uncommon patterns should be restricted to occasional tumours, usually originating in the transition zone, that were only diagnosable in transurethral resections or radical prostatectomy specimens. As a consequence of this, the Gleason scale for biopsies started at Gleason score six. Cribriform patterns, with the exception of the uncommon small, round, and regular cribriform structures, and so-called poorly formed glands (without well-formed lumens) were included as features of Gleason pattern (grade) 4. Additionally, it was decided that in biopsies where three Gleason patterns are present, the dominant pattern and worst remaining one, irrespective of its extent should comprise the Gleason score.

Over the following decade, the changes endorsed by ISUP in 2005 resulted in an upgrading of prostate cancer, with a greater proportion of patients being classified within high-risk categories.⁵⁻⁷ Additionally, the recalibration of

the Gleason scale resulted in practical problems for both urologists and oncologists, who had to explain to patients that Gleason 6 cancer was a low-grade tumour and that active surveillance, in many cases, was the treatment of choice. With the availability of information from the web and other sources, patients were often left confused by the concept of Gleason 6 being considered the most favourable grade on biopsy, when the Gleason system spanned scores 2–10. They were asking, “Wouldn’t my Gleason 6 cancer be considered intermediate grade?” Even for stratification of patients into a high-profile clinical trial, Gleason 6 was considered intermediate-grade rather than low-grade.⁸ Additionally, there was a suggestion by some clinicians, epidemiologists, and public health physicians to re-name Gleason 6 adenocarcinoma as “indolent lesion of epithelial origin (IDLE).”⁹

Because of these and other unresolved issues from the 2005 consensus conference, the ISUP convened a second meeting in 2014 to further clarify details of prostate cancer grading based on evidence generated since 2005 wherever possible. This conference was attended by 65 pathologists and 17 clinicians from 19 countries.¹⁰ At the meeting it was agreed that all cribriform and glomeruloid patterns should be classified as Gleason grade 4. It was further agreed that grading for mucinous tumours should be based upon the underlying architectural pattern and not be influenced by the mucin component. Finally, intraductal carcinoma of prostate, which has come to prominence as an important adverse prognostic factor in the last decade, would not be graded and only the associated invasive component would be assigned a Gleason score.

A major focus of the 2014 meeting was the refinement and endorsement of a prognostic grouping system initially proposed by Eifler et al in 2012.¹¹ Over the years, numerous grade grouping systems have been proposed and the current system is a natural progression of this (Table 1).¹²⁻²⁵ The ISUP grades, which are based on the grouping of Gleason scores and patterns, are shown in Table 2. Arguably, the

Table 1. Chronological evolution of the Gleason score/grade groupings*

Year	Gleason groupings	Reference
1977	2-3 v 4-5 v 6 v 7-8 v 9-10	Gleason ¹²
1987	2-5 v 6-7 v 8-10	Pilepich ¹³
1990	2-5 v 6 v 7 v 8-10	Bagshaw ¹⁴
1991	2-4 v 5-7 v 8-10	Russell ¹⁵
1993	2-6 v 7-10	Epstein ¹⁶
1994	2-4 v 5-6 v 7 v 8-10	Ohori ¹⁷
1995	2-3 v 4-6 v 7 v 8-10	Zagars ¹⁸
1997	2-4 v 5 v 6 v 7 v 8-10	Partin ¹⁹
1998	2-6 v 7 v 8-10	D'Amico ²⁰
2000	2-4 v 5-6 v 7-10	Freedland ²¹
2006	<6 v 3+4 v 4+3 v 8-10	Donohue ²²
2007	2-6 v 3+4 v 4+3 v 8-10	Makarov ²³
2011	≤3+4 v 4+3 v 8 v 9-10	Tolonen ²⁴
2012	2-6 v 3+4 v 4+3 v 8 v 9-10**	Eifler ¹¹

*Modified from Egevad et al²⁵; **refined and endorsed at International Society of Urological Pathology consensus conference (2014).

most significant element of the new system is the grouping of all cases with Gleason scores ≤6 as grade 1. The identification of this very low-risk category helps alleviate patients' concerns regarding the intermediate placement of Gleason score 6 tumours on the 2–10 Gleason scale. Many patients with these low-grade tumours can be followed by active surveillance and the reclassification of these as ISUP grade 1 emphasizes their indolent nature.

ISUP grades 2 and 3 stratify Gleason 7 into two categories based on whether well-formed glands or poorly formed/fused/cirribriform glands predominate. These two categories have long been known to have different prognostic significance and in fact, Gleason scores 7 (3 + 4) and 7 (4 + 3) have been incorporated into nomograms and risk calculators for many years.²⁶⁻²⁸ Subsequent to the 2014 consensus meeting, it was decided by the ISUP working group that the percentage pattern 4 should be documented in all Gleason 7 tumours, with agreement for this decision being obtained from participants by web-polling. The documentation of percentage pattern 4 is particularly important in ISUP grade 2 cancers, as the active surveillance guideline published by Cancer Care Ontario and subsequently endorsed by the American Society of Clinical Oncology, indicates that selected patients with Gleason 7 tumours who have ≤10% pattern 4 tumour, can be considered for active surveillance protocols.^{29,30} The documentation of percent pattern 4 in Gleason 7 cancers is also recently recommended by the WHO.³¹

The grade 4 category of the ISUP grading system is heterogeneous and consists predominantly of tumours with Gleason score 4 + 4 = 8, with less common Gleason patterns 3 + 5 and 5 + 3 also being included. These tumours behave in a significantly more aggressive manner than ISUP

Table 2. The International Society of Urological Pathology (ISUP) grading system

ISUP grade	Gleason scores	Definition
Grade 1	2–6	Only individual discrete well-formed glands
Grade 2	3+4=7	Predominantly well-formed glands with lesser component of poorly formed/fused/cirribriform glands
Grade 3	4+3=7	Predominantly poorly formed/fused/cirribriform glands with lesser component of well-formed glands
Grade 4	4+4=8	Only poorly formed/fused/cirribriform glands
	3+5=8	Predominantly well-formed glands and lesser component lacking glands (or with necrosis)
	5+3=8	Predominantly lacking glands (or with necrosis) and lesser component of well-formed glands
Grade 5	9–10	Lacking gland formation (or with necrosis) with or without poorly formed/fused/cirribriform glands

grade 3.³²⁻³⁴ Grade 5 is the highest ISUP grade and consists of Gleason scores 9 and 10. These latter tumours are associated with poor prognosis.³²⁻³⁴ From a practical perspective, it is recommended that the ISUP grade be reported in all needle biopsies, along with the corresponding Gleason patterns and scores.¹⁰

While ISUP grading represents a significant advance in prostate pathology, future modifications will likely be required. In particular, ISUP grade 4 tumours consisting of Gleason patterns 5 + 3 have been shown to have the worst prognosis compared to those with only pattern 4 or 3 + 5 and may be more appropriately included in ISUP grade 5.³⁵ Other problem areas include the level (individual core, specimen, case) at which ISUP grading should apply, the handling of grade diversity across specimens, and whether ISUP grade should be based on the worst or composite Gleason score. A further major unresolved issue is the lack of consensus as to how tertiary patterns should be handled in radical prostatectomy specimens.

Despite these issues, the ISUP grading system addresses several of the criticisms faced by urological pathologists related to the inaccuracy of Gleason scale and perceived over-diagnosis of cancer. Furthermore, and most importantly, it provides patients with low-risk disease the lowest possible grade. Indeed, one is the new six.

Competing interests: Dr. Evans has been a consultant on clinical trial design for GE/Omnix. The remaining authors report no competing personal or financial interests.

This paper has been peer-reviewed.

References

- Gleason DF. Classification of prostatic carcinomas. *Cancer Chemother Rep* 1966;50:125-28.
- Eble JN, Sauter G, Epstein JI, Sesterhenn I (Eds): *WHO Classification: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs*, 3rd ed. Lyon: IARC Press, 2004.
- Sobin L, Gospodarowicz M, Wittekind C. TNM classification of malignant tumours. In: *UICC*, 7th ed.: Wiley-Liss, 2009.
- Epstein JI, Allsbrook WC Jr, Amin MN, et al. ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. *Am J Surg Pathol* 2005;29:1228-42. <http://dx.doi.org/10.1097/01.pas.0000173646.99337.b1>
- Helpap B, Egevad L. The significance of modified Gleason grading of prostatic carcinoma in biopsy and radical prostatectomy specimens. *Virchows Arch* 2006;449:622-7. <http://dx.doi.org/10.1007/s00428-006-0310-6>
- Billis A, Guimaraes MS, Freitas LL, et al. The impact of the 2005 International Society of Urological Pathology consensus conference on standard Gleason grading of prostatic carcinoma in needle biopsies. *J Urol* 2008;180:548-52. <http://dx.doi.org/10.1016/j.juro.2008.04.018>
- Kuroiwa K, Uchino H, Yokomizo A, et al. Impact of reporting rules of biopsy Gleason score for prostate cancer. *J Clin Pathol* 2009;62:260-3. <http://dx.doi.org/10.1136/jcp.2008.060632>
- Resnick MJ, Koyama T, Fan KH, et al. Long-term functional outcomes after treatment for localized prostate cancer. *N Engl J Med* 2013;368:436-45. <http://dx.doi.org/10.1056/NEJMoa1209978>
- Esserman LJ, Thompson IM, Reid B, et al. Addressing over-diagnosis and overtreatment in cancer: A prescription for change. *Lancet Oncol* 2014;15:e234-42. [http://dx.doi.org/10.1016/S1470-2045\(13\)70598-9](http://dx.doi.org/10.1016/S1470-2045(13)70598-9)
- Epstein JI, Egevad L, Amin MB, et al. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: Definition of grading patterns and proposal for a new grading system. *Am J Surg Pathol* 2016;40:244-52.
- Eifler JB, Feng Z, Lin BM, et al. An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. *BJU Int* 2012;111: 22-9. <http://dx.doi.org/10.1111/j.1464-410X.2012.11324.x>
- Gleason DF and The Veterans Administration Cooperative Urological Research Group. Histologic grading and clinical staging of prostate carcinoma. In: Tannenbaum M (Ed). *Urologic Pathology*. Philadelphia: Lea and Febiger, 1977.
- Pilepich MV, Krall IM, Sause WT, et al. Prognostic factors in carcinoma of the prostate: Analysis of RTOG 75-06. *Int J Radiat Oncol Biol Phys* 1987;13:339-49. [http://dx.doi.org/10.1016/0360-3016\(87\)90007-1](http://dx.doi.org/10.1016/0360-3016(87)90007-1)
- Bagshaw MA, Cox RS, Ramback JE. Radiation therapy for localized prostate cancer: Justification by long-term followup. *Urol Clin Nth Am* 1990;17:787-802.
- Russell KJ, Dunatov C, Hafermann MD, et al. Prostate-specific antigen in the management of patients with localized adenocarcinoma of the prostate treated with primary radiation therapy. *J Urol* 1991;146:1046-52.
- Epstein JI, Carmichael M, Partin AW, et al. Is tumour volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with five years of followup. *J Urol* 1993;149:1478-81.
- Ohari M, Goad JR, Wheeler TM, et al. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? *J Urol* 1994;152:1843-49.
- Zagers GK, Ayala AG, von Eschenbach AC, et al. The prognostic importance of Gleason grade in prostatic adenocarcinoma: A long-term followup study of 648 patients treated with radiation therapy. *Int J Radiat Oncol Biol Phys* 1995;31:237-45. [http://dx.doi.org/10.1016/0360-3016\(94\)00323-D](http://dx.doi.org/10.1016/0360-3016(94)00323-D)
- Partin AW, Kattan MW, Subong ENP, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update. *JAMA* 1997;277:1445-51. <http://dx.doi.org/10.1001/jama.1997.03540420041027>
- D'Amico AV, Whittington R, Malkowicz SB, et al. The combination of preoperative prostate-specific antigen and preoperative pathological findings to predict prostate-specific antigen outcome in clinically localized prostate cancer. *J Urol* 1998;160:2096-101. [http://dx.doi.org/10.1016/S0022-5347\(01\)62251-1](http://dx.doi.org/10.1016/S0022-5347(01)62251-1)
- Freedland SJ, Sutter ME, Naitoh J, et al. Clinical characteristics in Black and White men with prostate cancer in an equal access medical centre. *Urology* 2000;55:387-90. [http://dx.doi.org/10.1016/S0090-4295\(99\)00461-6](http://dx.doi.org/10.1016/S0090-4295(99)00461-6)
- Donohue JF, Bianco FJ Jr, Kuroiwa K et al. Poorly differentiated prostate cancer treated with radical prostatectomy: Long-term outcome and incidence of pathological downgrading. *J Urol* 2006;176:991-5. <http://dx.doi.org/10.1016/j.juro.2006.04.048>
- Makarov DV, Trock BJ, Humphreys EB, et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. *Urology* 2007;69:1095-101. <http://dx.doi.org/10.1016/j.urology.2007.03.042>
- Tolonen TT, Kujala PM, Tammela LJ, et al. Overall and worst Gleason scores are equally good predictors of prostate cancer progression. *BMC Urology* 2011;11:21. <http://dx.doi.org/10.1186/1471-2490-11-21>
- Egevad L, Delahunt B, Evans AJ, et al. International Society of Urological Pathology (ISUP) grading of prostate cancer. *Am J Surg Pathol* 2016;40:858-61. <http://dx.doi.org/10.1097/PAS.0000000000000642>
- Makarov DV, Sanderson H, Partin AW, et al. Gleason score 7 prostate cancer on needle biopsy: Is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores? *J Urol* 2002;167:2440-2. [http://dx.doi.org/10.1016/S0022-5347\(05\)65000-8](http://dx.doi.org/10.1016/S0022-5347(05)65000-8)
- Wright JL, Solinas CA, Lin DW, et al. Prostate cancer specific mortality and Gleason 7 disease differences in prostate cancer outcomes between cases with Gleason 4 + 3 and Gleason 3 + 4 tumours in a population-based cohort. *J Urol* 2009;182:2702-7. <http://dx.doi.org/10.1016/j.juro.2009.08.026>
- Zumsteg ZS, Spratt DE, Pei I, et al. A new risk classification system for therapeutic decision-making with intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy. *Eur Urol* 2013;64:895-902. <http://dx.doi.org/10.1016/j.eururo.2013.03.033>
- Morash C, Tey R, Agbassi C, et al. Active surveillance for the management of localized prostate cancer: Guideline recommendations. *Can Urol Assoc J* 2015;9:171-8. <http://dx.doi.org/10.5489/cuaj.2806>
- Chen RC, Rumble RB, Loblaw DA, et al. Active surveillance for the management of localized prostate cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology clinical practice guideline endorsement. *J Clin Oncol* 2016;34:1-10. <http://dx.doi.org/10.1200/JCO.2015.65.7759>
- Moch H, Humphrey PA, Ulbright TM, Reuter RE (Eds.). *WHO Classification of Tumours of the Urinary System and Male Genital Organs*, 4th ed. [Lyon]: IARC Press, 2016.
- Samaratunga H, Delahunt B, Gianduzzo T, et al. The prognostic significance of the 2014 International Society of Urological Pathology (ISUP) grading system for prostate cancer. *Pathology* 2015;47:515-9. <http://dx.doi.org/10.1097/PAT.0000000000000315>
- Delahunt B, Egevad L, Srigley JR, et al. Validation of International Society of Urological Pathology (ISUP) grading for prostatic adenocarcinoma in thin core biopsies using TROG Q3.04 RADAR trial clinical data. *Pathology* 2015;47:520-5. <http://dx.doi.org/10.1097/PAT.0000000000000318>
- Epstein JI, Zelefsky MJ, Sjöberg DD, et al. A contemporary prostate cancer grading system: A validated alternative to the Gleason score. *Eur Urol* 2016;69:428-35. <http://dx.doi.org/10.1016/j.eururo.2015.06.046>
- Mahal BA, Muralidhar V, Chen YW, et al. Gleason score 5 + 3 = 8 prostate cancer: Much more like Gleason score 9? *BJU Int* 2016;118:95-101. <http://dx.doi.org/10.1111/bju.13239>

Correspondence: Dr. John R. Srigley, Trillium Health Partners and University of Toronto, Mississauga, ON, Canada; john.srigley@trilliumhealthpartners.ca